₹2266.65 -38.6 -1.7%
Last Trade - 3:55am
| Market Cap | £1.86bn |
| Enterprise Value | £1.78bn |
| Revenue | £141.9m |
| Position in Universe | 191st / 3056 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6,596 | 7,913 | 9,124 | 10,569 | 12,034 | 13,304 | 15,502 | 17,904 | +15.1% | ||
| +21.5 | +36.8 | +18.0 | +9.8 | +15.9 | +13.3 | +23.5 | +22.1 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Dr. Lal PathLabs Limited is engaged in providing diagnostic and related healthcare tests and services. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. The Company's geographical segments include India and Outside India. The Company offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of liver, disorders of bone, drugs of abuse, infertility, lymphoma, water purity, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, pregnancy and viral infections. The Company's other offerings include diabetes care program, loyalty card and wellness card.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | February 14, 1995 |
| Public Since | December 23, 2015 |
| No. of Shareholders: | 61,898 |
| No. of Employees: | 3,923 |
| Sector | Healthcare |
| Industry | Healthcare Providers & Services |
| Index | |
| Exchange | National Stock Exchange of India |
| Shares in Issue | 82,589,451 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 12th Floor,Tower B SAS Tower Sector 38 Medicity, GURGAON, 122001, India |
| Web | https://www.lalpathlabs.com/ |
| Phone | +91 124 3016557 |
| Contact | Ved Goel (IR Contact Officer) |
| Auditors | Deloitte Haskins & Sells LLP |
As of 3:55am, shares in Dr. Lal PathLabs are trading at ₹2266.65, giving the company a market capitalisation of £1.86bn. This share price information is delayed by 15 minutes.
Shares in Dr. Lal PathLabs are currently trading at ₹2266.65 and the price has moved by 40.17% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Dr. Lal PathLabs price has moved by 8.94% over the past year.
Of the analysts with advisory recommendations for Dr. Lal PathLabs, there are there are currently 1 "buy" , 3 "hold" and 2 "sell" recommendations. The overall consensus recommendation for Dr. Lal PathLabs is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Dr. Lal PathLabs is scheduled to issue upcoming financial results on the following dates:
The Dr. Lal PathLabs dividend yield is 0.52% based on the trailing twelve month period.
Last year, Dr. Lal PathLabs paid a total dividend of 12, and it currently has a trailing dividend yield of 0.52%. Looking ahead, Dr. Lal PathLabs has not announced an ex-dividend date yet and the next dividend pay date is 2021-02-27.
Dr. Lal PathLabs has yet to annouce their ex-dividend date and the next dividend pay date is 2021-02-27. The historic dividend yield on Dr. Lal PathLabs shares is currently 0.52%.
To buy shares in Dr. Lal PathLabs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Dr. Lal PathLabs are currently trading at ₹2266.65, giving the company a market capitalisation of £1.86bn.
Here are the trading details for Dr. Lal PathLabs:
Based on an overall assessment of its quality, value and momentum, Dr. Lal PathLabs is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Dr. Lal PathLabs are currently priced at ₹2266.65. At that level they are trading at 5.95% premium to the analyst consensus target price of 0.00.
Analysts covering Dr. Lal PathLabs currently have a consensus Earnings Per Share (EPS) forecast of 33.788 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dr. Lal PathLabs. Over the past six months, the relative strength of its shares against the market has been -5.11%. At the current price of ₹2266.65, shares in Dr. Lal PathLabs are trading at 14.34% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dr. Lal PathLabs PE ratio based on its reported earnings over the past 12 months is 79.26. The shares are currently trading at ₹2266.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dr. Lal PathLabs's management team is headed by:
Here are the top five shareholders of Dr. Lal PathLabs based on the size of their shareholding:
